Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients
Condition(s) studied
Investigational drug(s) / intervention(s)
PIPAC: PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg. During PIPAC, oxaliplatin 46 mg/m2 in 150 ml dextrose will be intraperitoneally nebulized at a rate of 0.5 ml/s with a maximum pressure of 200 PSI. The intraperitoneal air will be evacuated after 30 minutes of simple diffusion
Study summary
In this study, patients will be offered two Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) treatments with oxaliplatin after primary resection and standard adjuvant chemotherapy (if indicated) for colon cancer. Furthermore, the study will explore, whether it is possible to find free intraperitoneal tumor cells (FITC) after resection and adjuvant chemotherapy for colon cancer.
Eligibility
Primary outcome measure(s)
- The number of patients with peritoneal recurrence — 3 years
Based on contrast enhanced CT of the thorax and abdomen 36 months after resection of high-risk colon cancer.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Odense PIPAC Center, Department of Surgery, Odense University Hospital | Odense | Denmark | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03280511 on ClinicalTrials.gov ↗ ← All trials in Denmark